FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule
The U.S. Department of Justice has proposed rescheduling FDA-approved cannabis-derived products from Schedule I to Schedule III, recognizing their medical utility while maintaining controlled substance oversight. This cannabis schedule III…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
Policy Watch: 20 Regulatory Updates — June 08, 2026
Policy WatchJune 08, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Policy Watch: 10 Regulatory Updates — June 02, 2026
Policy WatchJune 02, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…